China's Neuracle performs first commercial BCI implant
Analysis based on 11 articles · First reported Jul 06, 2026 · Last updated Jul 16, 2026
The commercial approval of NEO positions Neuracle as a leader in the BCI market, potentially attracting investment and accelerating China's neurotechnology industry. Neuralink faces increased competitive pressure to secure FDA approval, while the broader BCI sector may see heightened investor interest and regulatory developments.
Chinese surgeons at Huashan Hospital in China — Shanghai performed the world's first commercial implantation of a brain-computer interface (BCI) using the NEO device developed by Neuracle. The patient, who suffered a spinal cord injury in a car accident ten years ago, received the coin-sized implant on the brain's surface to control a robotic glove. The procedure followed regulatory approval from China's China — National Medical Products Administration in March 2026, making NEO the first commercially approved invasive BCI. This milestone puts Neuracle ahead of Neuralink, which is still in clinical trials in the United States. The event highlights China's strategic push to lead in neurotechnology, with government support and a goal to develop globally competitive BCI companies by 2030. The NEO device is less invasive than Neuralink's, as it sits on the dura mater rather than penetrating brain tissue. Other companies like Beckman Coulter and Meta are also pursuing BCI technologies. The commercial approval raises ethical questions about data privacy and cybersecurity, but offers hope for patients with paralysis.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard